surpass-cvot tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular Outcomes in Type 2 Diabetes Read now: The SURPASS-EARLY trial

They also show promise for the treatment of many inflammatory diseases including asthma and inflammatory bowel disorders like Crohns disease and ulcerative colitis Diagram showing food stimulating the release of GLP-1 into the intestine and its effects on the brain, stomach and pancreas Importance In 2023 GLP-1 based drugs was named breakthrough of the year by Science , a prestigious American journal

De Fano M, Baluganti S, Manco M , et al

Ingwersen is employed by and holds stock in Novo Nordisk

Worsening metabolic markers during dose reduction are a clear signal that your body needs more pharmacological support, regardless of what the scale says

12 Concluding Encouragement Taking charge of health with GLP-1 medications is a commendable step

Historically, tearing a tendon or ligament meant facing a grueling, months-long recovery